The preservation of HDAC1, HDAC2, and HDAC5 expression suggests that BKS-112 may offer reduced toxicity compared to pan-HDAC inhibitors while maintaining potent anticancer activity through coordinated inhibition of HDAC6, HDAC3, and HDAC4, which are critically involved in cancer cell survival, proliferation, and metastasis. Here, HDAC3 is linked to cancer.